SCENESSE - Afamelanotide -
EMEA/H/C/002548/II/0052, Orphan
Clinuvel Europe Limited, Rapporteur: Janet
Koenig, PRAC Rapporteur: Martin Huber ,
“Update of section 4.2 of the SmPC in order to
update the posology recommendations by
removing the current recommendation of a
maximum of four implants per year, based on a
literature review and analysis of safety data.
The Package Leaflet is updated accordingly. The
RMP version 9.8 has also been submitted. In
addition, the MAH took the opportunity to
introduce a minor editoria
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-27-30-may-2024_en.pdf
Scenesse expanding to 4+ implants annually in the EU?
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.59 |
Change
-0.150(1.02%) |
Mkt cap ! $730.6M | |||
| Open | High | Low | Value | Volume |
| $14.74 | $14.77 | $14.50 | $504.1K | 34.46K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 132 | $14.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.64 | 96 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |